BAYN Stock Overview
Together its subsidiaries, operates as a life science company worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €27.07 |
| 52 Week High | €53.80 |
| 52 Week Low | €24.96 |
| Beta | 0.95 |
| 1 Month Change | -5.30% |
| 3 Month Change | 3.24% |
| 1 Year Change | -48.28% |
| 3 Year Change | -48.69% |
| 5 Year Change | -50.63% |
| Change since IPO | 98.72% |
Recent News & Updates
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Jun 11
The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet
May 07Recent updates
These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt Extensively
Jun 11The Market Doesn't Like What It Sees From Bayer Aktiengesellschaft's (ETR:BAYN) Revenues Yet
May 07These 4 Measures Indicate That Bayer (ETR:BAYN) Is Using Debt In A Risky Way
Jan 18Are Investors Undervaluing Bayer Aktiengesellschaft (ETR:BAYN) By 42%?
Dec 27Bayer (ETR:BAYN) Takes On Some Risk With Its Use Of Debt
Oct 15Bayer Aktiengesellschaft (ETR:BAYN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Aug 05Is Bayer (ETR:BAYN) A Risky Investment?
Jun 28Bayer (ETR:BAYN) Use Of Debt Could Be Considered Risky
Dec 07Shareholder Returns
| BAYN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.6% | -0.7% | -3.1% |
| 1Y | -48.3% | -18.1% | -0.5% |
Return vs Industry: BAYN underperformed the German Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: BAYN underperformed the German Market which returned -0.5% over the past year.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: BAYN has not had significant price volatility in the past 3 months.
Volatility Over Time: BAYN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 98,189 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market cap | €26.59b |
| Earnings (TTM) | -€3.12b |
| Revenue (TTM) | €47.01b |
0.6x
P/S Ratio-8.5x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €47.01b |
| Cost of Revenue | €19.48b |
| Gross Profit | €27.54b |
| Other Expenses | €30.66b |
| Earnings | -€3.12b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | -3.17 |
| Gross Margin | 58.57% |
| Net Profit Margin | -6.63% |
| Debt/Equity Ratio | 129.4% |
How did BAYN perform over the long term?
See historical performance and comparison